Summary of Conference Call Company and Industry Overview - The conference call primarily focused on a pharmaceutical company, specifically discussing its product, Obutini, and its positioning in the hematology and autoimmune disease treatment markets [1][10]. Core Points and Arguments 1. **Core Recommendation Logic**: The company believes that Obutini has both short-term performance certainty and long-term growth potential, driven by its sales growth in the hematology sector [1][12]. 2. **Sales Guidance Adjustments**: Over the past year, the company has consistently raised its global sales guidance for Obutini, from an initial estimate of 30% growth to a final projection of 49% to 50%, with absolute sales expected to reach 1 billion [2][12]. 3. **Market Potential in Hematology**: The company anticipates significant growth in Obutini's sales, particularly in the marginal zone 08 lymphoma indication, which is expected to maintain its competitive advantage [2][5]. 4. **Sales Projections for Clinical Trials**: The sales for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are projected to grow from approximately 300 million to 350 million, with a notable increase expected in 2026 due to new trial launches [3][4]. 5. **MCL Sales Forecast**: The company estimates that the sales peak for MCL (Mantle Cell Lymphoma) could reach around 720 million, with future sales potential of 1 billion [4][5]. 6. **Overall Market Size**: The company projects that the total sales potential for Obutini in hematology could reach between 2.5 billion to 3 billion, indicating a significant market opportunity [5][12]. 7. **Expansion Beyond Hematology**: The company is also exploring opportunities in the autoimmune disease sector, which has a larger patient population compared to hematology, thus extending Obutini's product lifecycle and sales ceiling [6][7][10]. 8. **International Market Strategy**: The company is actively pursuing international market opportunities, which could further enhance Obutini's sales potential [7][9]. 9. **Product Pipeline**: The company has a diverse product pipeline beyond Obutini, including several candidates in various stages of clinical trials, which supports its long-term growth strategy [10][11][34]. 10. **Financial Projections**: The company forecasts sales revenues of 1 billion, 1.39 billion, and 1.92 billion for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 35%, 46%, and 32% [13][35]. 11. **Improving Profitability**: The company has shown continuous improvement in gross margins and operational efficiency, with expectations of turning losses into profits in the near future [14][15][16]. 12. **Market Trends in Hematology**: The hematology market is projected to grow at a CAGR of 10.5% to 13.5% from 2024 to 2028, driven by advancements in treatment modalities [18][20]. Other Important Insights - **Differentiated Positioning**: Obutini's unique molecular structure enhances its selectivity, safety, and efficacy compared to other treatments, positioning it favorably in the market [23][25]. - **Regulatory Milestones**: The company is anticipating several key regulatory milestones in the coming years, which could significantly impact its market position and sales trajectory [12][34]. - **Collaborative Opportunities**: The company is exploring business development opportunities to enhance its product offerings and market reach [17][32]. This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic focus, market potential, and financial outlook.

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年2月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底法 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Views - The company is a leading player in the hematological malignancies sector, with its core product, Obutinib, demonstrating solid advantages in efficacy, safety, and patient affordability compared to other BTK inhibitors [1][2]. - Obutinib has received approval for the treatment of relapsed/refractory marginal zone lymphoma (MZL), making it the only BTK inhibitor with this indication in China, which is expected to accelerate its sales growth [1]. - The company forecasts Obutinib's sales to reach 1.001 billion RMB in 2024, representing a 49% year-on-year increase, while the net loss is projected to decrease by 30% to 443 million RMB [1][4]. Summary by Sections Investment Logic - The company has established a leadership position in the domestic hematological malignancies market, with Obutinib as a second-generation BTK inhibitor showing superior efficacy and safety [1]. - The approval of Obutinib for MZL is expected to significantly boost its sales [1]. - The company anticipates substantial improvement in operational performance, with a projected sales revenue of 1.001 billion RMB for 2024, a 49% increase year-on-year, and a reduction in net loss to 443 million RMB [1]. Pipeline and Expansion - Obutinib is expected to receive approval for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL) in 2025/2026, which will inject new growth momentum into its sales [2]. - The company is also advancing Obutinib's clinical trials for primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS), where treatment options are currently limited [2]. - The company has a robust pipeline with multiple products in various stages of clinical development, including therapies for autoimmune diseases and solid tumors [3][30]. Financial Projections - The company projects sales revenues of approximately 1.001 billion RMB, 1.457 billion RMB, and 1.919 billion RMB for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 35%, 46%, and 32% [4][7]. - The net loss is expected to decrease from 443 million RMB in 2024 to 301 million RMB in 2025 and further to 187 million RMB in 2026 [4][7]. - The target price based on DCF valuation is set at 14.77 RMB per share, indicating significant upside potential [4].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2025年1月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09969 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

根据开曼群岛法律、适用上市规则、公司章程及《提名委员会章程》的有关 规定，依据独立非执行董事候选人声明承诺、独立性声明、个人履历等信息，公 司董事会提名委员会于 2025 年 1 月 21 日举行会议，对独立非执行董事候选人的 任职资格进行了审核，就委任独立非执行董事向董事会提出如下意见： 本委员会已审阅 Kunliang Guan(管坤良)教授的背景资料及个人履历，认为 其符合开曼群岛法律、适用上市规则、公司章程及《提名委员会章程》规定的独 立非执行董事任职资格。本委员会决议通过向董事会提呈有关委任 Kunliang Guan(管坤良)教授为公司董事会独立非执行董事之决议案。 诺诚健华医药有限公司 董事会提名委员会 2025 年 1 月 21 日 诺诚健华医药有限公司 董事会提名委员会关于委任独立非执行董事的意见 ...

Group 1: Financial Performance - The company expects revenue from Oubatinib to reach approximately RMB 1,001 million in 2024, representing a growth of about 49% compared to the previous year [1] - The total operating revenue is projected to be around RMB 1,010 million, reflecting a growth of approximately 37% year-on-year [1] - The net profit attributable to the parent company is expected to be around RMB -443 million, indicating a reduction in losses by about 30% compared to the previous year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be around RMB -444 million, showing a decrease in losses of approximately 29% year-on-year [1] - In 2023, the company reported an operating revenue of RMB 739 million, a year-on-year increase of 18.09% [1] - The net profit attributable to shareholders was RMB -631 million in 2023, compared to RMB -887 million in 2022 [1] - The net profit after deducting non-recurring gains and losses was RMB -626 million in 2023, compared to RMB -960 million in 2022 [1] - The net cash flow from operating activities was RMB -665 million in 2023, compared to RMB -491 million in 2022 [1] - The company has reported losses for six consecutive years [1] Group 2: IPO and Fundraising - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 21, 2022, with an initial public offering of 264,648,217 shares at a price of RMB 11.03 per share [2] - The total amount raised from the initial public offering was RMB 2,919.07 million, with a net amount of RMB 2,778.82 million after expenses [3] - The actual net fundraising amount was RMB 122.12 million less than the originally planned amount of RMB 4,000 million [4] - The funds were intended for new drug research and development, upgrading drug research platforms, building marketing networks, information technology construction, and supplementing working capital [4] - The total issuance costs for the initial public offering amounted to RMB 140.25 million, with underwriting and sponsorship fees accounting for RMB 112.17 million [5]

Revenue Projections - The company expects revenue from Obinutuzumab to be approximately RMB 1,001 million in 2024, representing a growth of about 49% compared to the previous year[4]. - Total operating revenue is projected to be around RMB 1,010 million, reflecting a growth of approximately 37% year-over-year[4]. - The sales revenue of Obinutuzumab has increased by about 49% due to its coverage under medical insurance for three indications, including being the first and only BTK inhibitor approved for marginal zone lymphoma in China[6]. Net Loss Estimates - The net loss attributable to the parent company is estimated at RMB 443 million, a reduction of about 30% compared to the previous year[4]. - The net loss attributable to the parent company, after deducting non-recurring gains and losses, is expected to be around RMB 444 million, a decrease of approximately 29% year-over-year[4]. Research and Development - The company has increased its R&D investment by approximately 8.4% compared to the previous year, indicating a commitment to pipeline development[6]. Financial Stability - The company incurred an unrealized exchange loss of about RMB 33 million in 2024, which is less than the unrealized exchange loss from the previous year[6]. - The sales expense ratio has continuously decreased, enhancing the company's sustainable development capabilities[6]. - The company has not identified any significant uncertainties that would affect the accuracy of this earnings forecast[7]. Data Disclosure - The data provided is preliminary and subject to change, with the final audited financial data to be disclosed in the 2024 annual report[8].

主要原因包括奥布替尼销售收入增长约49%，销售费用率持续降低，研发投入增长8.4%，以及人民币对 美元汇率波动产生的未实现汇兑损失减少。 归属于母公司所有者的净利润预计为-4.43亿元左右，亏损减少30%左右。 《科创板日报》16日讯，诺诚健华发布2024年年度业绩预告，预计2024年奥布替尼实现收入10.01亿元 左右，同比增长49%左右；营业总收入10.1亿元左右，同比增长37%左右。 ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 購買價： 每股香港股份0.178美元（約1.39港元） 於授出日期股份的 (i) 每股香港股份6.12港元；及 收市價： 根據二零二三年股權激勵計劃 授予受限制股份單位 根據上市規則第17.06A條，董事會宣佈於二零二四年十二月三十一日，本公司 根據二零二三年股權激勵計劃授予六名承授人3,830,000份受限制股份單位，相 當於本公司於本公告日期已發行股份總數的約0.22%。 授予受限制股份單位的詳情 授予承授人受限制股份單位的詳情如下： 授出日期： 二零二四年十二月三十一日 承授人及獲授受限制股份 單位的數目： 授予六名僱員參與者3,830,000份受限制股份單位。 概無承授人須個別披露。 (ii) 每股人民幣股份人民幣12.28元（約13.26 ...